Media Newsroom of

Enterin Inc.

3624 Market St Suite 517
Philadelphia, PA 19104
Website: http://www.enterininc.com

About Enterin Inc.

Enterin Inc. is an early stage CNS pharmaceutical company located in Philadelphia, specializing in the treatment of neurodegenerative diseases caused by a dysfunctional gut-brain axis.

Recent Press Releases of Enterin Inc.

Enterin to Present at Chardan’s Virtual 3rd Annual Microbiome Medicines Summit

Enterin to Present at Chardan’s Virtual 3rd Annual Microbiome Medicines Summit

Mar 01, 2021 - Enterin Inc. (Press Release) - Enterin, Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative diseases, announces that the company will be presenting at Chardan's virtual 3rd Annual Microbiome Medicines Summit on March 8, 2021, at 8:30 a.m. ET.Dr. Denise Barbut, Enterin's…

Enterin Announces Appointment of Chief Financial Officer

Enterin Announces Appointment of Chief Financial Officer

Feb 24, 2021 - Enterin Inc. (Press Release) - Enterin, Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative diseases, announces the appointment of Katherine Wolf as Chief Financial Officer. Ms. Wolf brings 30 years of health care industry experience in capital raising, business development, and strategy,…

Enterin Announces Appointment of VP, Head Of Medical And Clinical Development

Enterin Announces Appointment of VP, Head Of Medical And Clinical Development

Oct 27, 2020 - Enterin Inc. (Press Release) - Enterin Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the appointment of Chris Min as VP, Head of Medical and Clinical Development. With over 19 years of experience as…

Enterin Announces Appointment of New CEO

Enterin Announces Appointment of New CEO

Oct 16, 2020 - Enterin Inc. (Press Release) - Enterin, Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the appointment of David McCullough as Chief Executive Officer. With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated…

Enterin to Conduct a Randomized Phase 1/2a Study in Hospitalized Patients With COVID-19

Enterin to Conduct a Randomized Phase 1/2a Study in Hospitalized Patients With COVID-19

Apr 17, 2020 - Enterin Inc. (Press Release) - Enterin, Inc., a clinical-stage company focused on neurodegenerative diseases, announced today that it has received feedback from the FDA laying out the path for a Phase 1/2a study in hospitalized patients with COVID-19 infection. The study will involve 10 U.S.…

Enterin's DEMET Study Enrolls First Patient With Parkinson's Disease Dementia (PDD)

Enterin's DEMET Study Enrolls First Patient With Parkinson's Disease Dementia (PDD)

Jun 24, 2019 - Enterin Inc. (Press Release) - ​Enterin Inc., a CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson’s disease (PD), has enrolled the first patient in the DEMET study. The study is an open label multi-center study involving patients with PDD and taking…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login